Effect of Longer-Interval vs Standard Dosing of Zoledronic Acid on Skeletal Events in Patients With Bone Metastases
Andrew L. Himelstein, Charles L. Shapiro(Icahn School of Medicine at Mount Sinai), Douglas Weckstein(New Hampshire Hospital), James Khatcheressian(Virginia Cancer Institute), Ronald S. Go(Mayo Clinic), Tracey L. O’Connor(Roswell Park Comprehensive Cancer Center), Drew K. Seisler(Mayo Clinic), Jared C. Foster(Mayo Clinic), Mario R. Velasco(Decatur Memorial Hospital), Rui Qin(Regeneron (United States)), John D. Roberts(National Institute of Environmental Health Sciences), Stephen S. Grubbs(American Society of Clinical Oncology), Charles L. Loprinzi(American Society of Clinical Oncology), Ann M. O’Mara(National Cancer Institute), Paul J. Novotny(Mayo Clinic)
Cited by 357
Related Papers
Symptom Monitoring With Patient-Reported Outcomes During Routine Cancer Treatment: A Randomized Controlled Trial
|Journal of Clinical Oncology|2015|2.6k
Prevention and Management of Chemotherapy-Induced Peripheral Neuropathy in Survivors of Adult Cancers: American Society of Clinical Oncology Clinical Practice Guideline
|Journal of Clinical Oncology|2014|1.2k
Development of the National Cancer Institute's Patient-Reported Outcomes Version of the Common Terminology Criteria for Adverse Events (PRO-CTCAE)
|JNCI Journal of the National Cancer Institute|2014|1.1k